Ken Griffin Biotechnology

Citadel Advisors LLC

  • $559 Billion
  • Q4 2024

Stock List

Stock Option Type Value Options Held Last Trade Trade History
INVA
Innoviva, Inc.
PUT
$13,000
800
Q4 2024
Reduced 35.41%
MRSN
Mersana Therapeutics, Inc.
PUT
$13,000
9.7K
Q4 2024
Reduced 90.45%
PDSB
Pds Biotechnology Corp
CALL
$13,000
8.3K
Q4 2024
Added 91.52%
RZLT
Rezolute, Inc.
PUT
$13,000
2.8K
Q4 2024
Reduced 15.05%
TNGX
Tango Therapeutics, Inc.
PUT
$13,000
4.4K
Q4 2024
Reduced 39.62%
TSHA
Taysha Gene Therapies, Inc.
PUT
$13,000
7.8K
Q4 2024
Reduced 73.94%
BTAI
Bio Xcel Therapeutics, Inc.
CALL
$12,000
34.5K
Q1 2024
Added 662.53%
CLSD
Clearside Biomedical, Inc.
PUT
$12,000
12.1K
Q3 2024
Reduced 25.9%
CGEN
Compugen LTD
PUT
$12,000
8.1K
Q4 2024
Added 55.98%
GLYC
Glycomimetics Inc
CALL
$12,000
51K
Q1 2024
Added 25.72%
OCUP
Ocuphire Pharma, Inc.
CALL
$12,000
12.6K
Q4 2024
Added 102.46%
CLSD
Clearside Biomedical, Inc.
CALL
$11,000
11.9K
Q3 2024
Reduced 25.9%
CUE
Cue Biopharma, Inc.
CALL
$11,000
10.8K
Q2 2024
Reduced 43.05%
ELDN
Eledon Pharmaceuticals, Inc.
PUT
$11,000
2.7K
Q4 2024
New holding
GANX
Gain Therapeutics, Inc.
CALL
$11,000
5.7K
Q4 2024
New holding
ADGI
Adagio Therapeutics, Inc.
CALL
$11,000
3.6K
Q4 2024
Reduced 89.51%
KPTI
Karyopharm Therapeutics Inc.
CALL
$11,000
17.5K
Q3 2024
Added 0.07%
RGLS
Regulus Therapeutics Inc.
PUT
$11,000
7K
Q4 2024
Added 486018.75%
SLGL
Sol Gel Technologies Ltd.
CALL
$11,000
12.8K
Q3 2024
Added 254.65%
ACXP
Acurx Pharmaceuticals, Inc.
CALL
$10,000
13.5K
Q2 2024
New holding
ADCT
Adc Therapeutics Sa
CALL
$10,000
5.1K
Q2 2024
Reduced 95.65%
ATHA
Athira Pharma, Inc.
CALL
$10,000
17.2K
Q2 2024
Reduced 50.65%
CRBU
Caribou Biosciences, Inc.
CALL
$10,000
6.8K
Q3 2024
Added 3.15%
ENLV
Enlivex Therapeutics Ltd.
PUT
$10,000
9.1K
Q1 2024
Added 683.59%
IMMP
Immutep LTD
CALL
$10,000
5K
Q4 2024
Reduced 92.61%
PDSB
Pds Biotechnology Corp
PUT
$10,000
6.7K
Q4 2024
Added 91.52%
PLX
Protalix Bio Therapeutics, Inc.
PUT
$10,000
5.3K
Q4 2024
Added 59.06%
PBYI
Puma Biotechnology, Inc.
PUT
$10,000
3.4K
Q4 2024
Added 2214.2%
AADI
Aadi Bioscience, Inc.
PUT
$9,000
3.1K
Q4 2024
Added 733.36%
IPSC
Century Therapeutics, Inc.
CALL
$9,000
9.7K
Q4 2024
Added 2714.17%
KRON
Kronos Bio, Inc.
CALL
$9,000
10K
Q4 2024
Added 114.12%
LYEL
Lyell Immunopharma, Inc.
PUT
$9,000
15.3K
Q4 2024
Added 211196.84%
TSVT
2seventy Bio, Inc.
PUT
$8,000
2.9K
Q4 2024
Added 10428.21%
ADAP
Adaptimmune Therapeutics PLC
PUT
$8,000
16.3K
Q4 2024
New holding
CSBR
Champions Oncology, Inc.
PUT
$8,000
1K
Q4 2024
New holding
ORMP
Oramed Pharmaceuticals Inc.
PUT
$8,000
3.5K
Q4 2024
Added 238.7%
PRLD
Prelude Therapeutics Inc
CALL
$8,000
6.4K
Q4 2024
Reduced 32.37%
ADAP
Adaptimmune Therapeutics PLC
CALL
$7,000
14.7K
Q4 2024
New holding
ACET
Adicet Bio, Inc.
CALL
$7,000
7.3K
Q4 2024
Reduced 53.04%
CVAC
Cure Vac N.V.
PUT
$7,000
2.3K
Q3 2024
Added 288.26%
EYEN
Eyenovia, Inc.
CALL
$7,000
52.5K
Q1 2024
Reduced 98.82%
INZY
Inozyme Pharma, Inc.
CALL
$7,000
2.6K
Q4 2024
Added 1144.77%
OLMA
Olema Pharmaceuticals, Inc.
PUT
$7,000
1.3K
Q4 2024
Added 34.36%
PMCB
Pharma Cyte Biotech, Inc.
PUT
$7,000
4.6K
Q1 2024
Reduced 70.09%
YMAB
Y M Abs Therapeutics, Inc.
PUT
$7,000
900
Q4 2024
Reduced 19.17%
ATNM
Actinium Pharmaceuticals, Inc.
PUT
$6,000
4.8K
Q4 2024
Added 1195.65%
BDTX
Black Diamond Therapeutics, Inc.
CALL
$6,000
2.9K
Q3 2024
Added 15437.73%
CNTA
Centessa Pharmaceuticals PLC
PUT
$6,000
400
Q4 2024
Added 6.43%
ADGI
Adagio Therapeutics, Inc.
PUT
$6,000
2.1K
Q4 2024
Reduced 89.51%
Filter Shares Options
Ken Griffin

Ken Griffin

Ken Griffin is the founder and CEO of Citadel Advisors, a successful investment firm that uses technology and data-driven approaches to investing. Griffin is known for his expertise in quantitative investing and his innovative approach to investing. He has generated strong returns for his clients over the long term.
Track Ken Griffin's portfolio
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email